Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agentes antineoplásicos - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lúpus eritematoso, sistêmico - imunossupressores - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - doença pulmonar, obstrução crônica - medicamentos para obstrutiva, doenças das vias respiratórias, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Portugall - Portugiż - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

miat, spa - diclofenac - emplastro medicamentoso - 140 mg - diclofenac hidroxietilpirrolidina 180 mg - diclofenac - n/a - duração do tratamento: curta ou média duração

Portugall - Portugiż - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

eurocept international b.v. - lidocaína + tetracaína - emplastro medicamentoso - 70 mg + 70 mg - lidocaína 70 mg ; tetracaína 70 mg - lidocaine, combinations - n/a - duração do tratamento: curta ou média duração

Portugall - Portugiż - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

eurocept international b.v. - lidocaína + tetracaína - emplastro medicamentoso - 70 mg + 70 mg - lidocaína 70 mg ; tetracaína 70 mg - lidocaine, combinations - n/a - duração do tratamento: curta ou média duração

Portugall - Portugiż - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

eurocept international b.v. - lidocaína + tetracaína - emplastro medicamentoso - 70 mg + 70 mg - lidocaína 70 mg ; tetracaína 70 mg - lidocaine, combinations - n/a - duração do tratamento: curta ou média duração

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.